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Abstract
Background: A number of Zika vaccine platforms are currently being investigated, some of which have entered
clinical trials. We sought to evaluate the cost-effectiveness of a potential Zika vaccine candidate under the WHO
Vaccine Target Product Profile for outbreak response, prioritizing women of reproductive age to prevent
microcephaly and other neurological disorders.
Methods: Using an agent-based simulation model of ZIKV transmission dynamics in a Colombian population
setting, we conducted cost-effectiveness analysis with and without pre-existing herd immunity. The model was
parameterized with estimates associated with ZIKV infection, risks of microcephaly in different trimesters, direct
medical costs, and vaccination costs. We assumed that a single dose of vaccine provides a protection efficacy in the
range 60% to 90% against infection. Cost-effectiveness analysis was conducted from a government perspective.
Results: Under a favorable scenario when the reproduction number is relatively low (R0 = 2.2) and the relative
transmissibility of asymptomatic infection is 10% compared with symptomatic infection, a vaccine is cost-saving
(with negative incremental cost-effective ratio; ICER) for vaccination costs up to US$6 per individual without herd
immunity, and up to US$4 per individual with 8% herd immunity. For positive ICER values, vaccination is highly
cost-effective for vaccination costs up to US$10 (US$7) in the respective scenarios with the willingness-to-pay of
US$6610 per disability-adjusted life-year, corresponding to the average per capita GDP of Colombia between 2013
and 2017. Our results indicate that the effect of other control measures targeted to reduce ZIKV transmission
decreases the range of vaccination costs for cost-effectiveness due to reduced returns of vaccine-induced herd
immunity. In all scenarios investigated, the median reduction of microcephaly exceeded 64% with vaccination.
Conclusions: Our study suggests that a Zika vaccine with protection efficacy as low as 60% could significantly
reduce the incidence of microcephaly. From a government perspective, Zika vaccination is highly cost-effective, and
even cost-saving in Colombia if vaccination costs per individual is sufficiently low. Efficacy data from clinical trials
and number of vaccine doses will be important requirements in future studies to refine our estimates, and conduct
similar studies in other at-risk populations.
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Background
In November 2016, following the decline of Zika virus
(ZIKV) outbreaks reported in 69 countries and territories
[1], the World Health Organization (WHO) ended its dec-
laration of ZIKV spread as a “public health emergency of
international concern” [2]. However, sporadic cases of
ZIKV infection have occurred [3], and the threat of large
outbreaks continues to exist in the absence of counter-
measures such as vaccination or prophylactic drugs, espe-
cially in susceptible populations where the primary
transmitting vector (i.e., Aedes aegypti mosquito) is en-
demic [4]. Although vector-control programs can mitigate
the impact of disease, ZIKV still remains an important
public health concern due to its potential to cause severe
outcomes and long-term sequelae, including microcephaly
with brain abnormalities and neurological disorders in in-
fants, and Guillain–Barré syndrome (GBS) in adults [5–7].
Previous studies indicate that a significant portion (up to
80%) of ZIKV-infected cases experience asymptomatic form
of disease, yet are still capable of contributing to virus
transmission [8]. There is also evidence that ZIKV can be
transmitted through sexual encounter [9–11]. Furthermore,
congenital ZIKV syndrome has been reported to occur in
the same proportion of women with asymptomatic as
symptomatic ZIKV infection during pregnancy [12]. These
considerations instigated global efforts for the development
of a safe and effective Zika vaccine. Currently, there are a
number of vaccine candidates being investigated using a
variety of vaccine platforms [13], including purified inacti-
vated, live attenuated, viral-vectored, virus-like particles, re-
combinant subunit, DNA, self-replicating RNA, and
mRNA [13, 14]. Experience with the development of other
flavivirus vaccines suggests that generating a preventive
Zika vaccine should be feasible [15, 16]. However, the
cost-effectiveness of a vaccine candidate will be a major fac-
tor in decisions regarding the implementation and strategic
use of vaccines in immunization programs.
In this study, we sought to investigate the cost-effectiveness
of a potential Zika vaccine candidate, taking into account
the WHO vaccine prioritization of women of reproductive
age [17], including pregnant women, to prevent prenatal
ZIKV infection and microcephaly as well as other severe
brain anomalies. For this investigation, we considered
the ‘outbreak response’ scenario prioritized in the
WHO/UNICEF ZIKV vaccine target product profile, and
employed an agent-based computational model to simulate
disease dynamics and derive outcomes for cost-effectiveness
analysis. We performed this analysis using parameter
estimates extracted from published studies with a plausible
range of costs for vaccine administration.
Methods
We extended a previously established agent-based
computational model of Zika infection dynamics as
the basic framework [18] to include vaccination and
Zika-associated congenital microcephaly during preg-
nancy. The comprehensive structure of the model en-
capsulates age-dependent individual attributes and
population heterogeneities, and simulates disease spread
in humans through vector (i.e., mosquitoes) and sexual
transmission (Additional file 1). The model was parame-
terized with a population demographic distribution similar
to that of Colombia, in which the health of every individ-
ual is characterized by several epidemiological statuses, in-
cluding susceptible, infected and incubating, infectious
and asymptomatic, infectious and symptomatic, and re-
covered. In the chain of ZIKV transmission, mosquitoes
exhibit the statuses of susceptible, infected and incubating,
and infectious. Infected mosquitoes remain infectious for
their entire lifespan. Our analysis was conducted for an
epidemic outbreak starting during a high-temperature
season.
Disease outcomes
There is evidence that associates the risk of microcephaly
in infants to Zika infection in all trimesters of pregnancy
[19], although the risk is significantly higher in the first and
second trimesters [12, 20]. Previous studies, considering
possible overreporting, have quantified the risk of develop-
ing microcephaly in both symptomatic and asymptomatic
pregnant women [21, 22]. We considered the associated
risks in a probabilistic approach to determine the micro-
cephaly outcome in pregnant women at the time of infec-
tion. Infants with microcephaly who survive their first year
of life were assumed to have significantly lower life expect-
ancy [23, 24]. We also considered the effect of neurological
and behavioral deficits due to microcephaly, leading to an
impaired quality of life, quantified by disability weights pro-
vided in the Global Burden of Disease study [25]. In
addition to neurological microcephaly, we considered the
risk of developing GBS in ZIKV-infected individuals [26].
Vaccination dynamics
Based on the WHO recommendations for vaccine
prioritization [17], we implemented vaccination in the
model for women between 15 and 49 years of age.
We also considered vaccination of other individuals
in the population between 9 and 60 years of age in
order to reduce the risk of disease transmission to
pregnant women. Vaccine-induced immunity reduced
the risk of infection based on the protection efficacy
sampled for each vaccinated individual. We assumed
that ZIKV infection following vaccination (if it oc-
curred) was asymptomatic without clinical manifest-
ation. Naturally acquired immunity was assumed to
provide full protection for a sufficiently long period
of time, so that the risk of re-infection within the
same epidemic season was eliminated.
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Parameterization
The baseline values and ranges of disease parameters in the
model are rigorously described in a previous study [18],
and are summarized in Table 1. This parameterization is
based on the estimates of the mean reproduction number
of R0 = 2.2 (95% CI 1.9–2.8) for Antioquia, Colombia [27],
and the mean attack rate of 8% (95% CI 4% and 26%)
[18, 28]. The risk of ZIKV-infected microcephaly during
the first trimester was sampled in the range 5% to 14%
[12, 20, 21]. This risk was reduced during the second and
third trimester, and was sampled in the range 3% to 5%
[12, 20]. The risk for developing GBS was between 0.025%
and 0.06% for both symptomatic and asymptomatic indi-
viduals [26]. All ZIKV-infected individuals with clinical
symptoms incurred short- and long-term direct medical
costs, depending on disease outcomes. Short-term costs
were associated with a physician visit (US$65) [29] and
diagnostic microcephaly test (US$150) for pregnant
women [30]. For microcephaly and GBS, we considered
lifetime direct medical costs of US$91,925 and US$29,027,
respectively [24, 30], which included hospitalization, treat-
ment, and other associated medical costs.
For vaccine implementation at the onset of simula-
tions, we assumed a conservative vaccination coverage
of 60% for non-pregnant women of reproductive age.
The coverage for pregnant women in the same age
group was set to 80% throughout the simulations. The
vaccine coverage for other individuals between 9 and
60 years of age was set to 10%. While some ZIKV vac-
cine candidates have entered phase 1 clinical trials, there
is currently no data available to indicate the level of
vaccine-induced protection and the number of vaccine
doses required. We therefore assumed that a single vac-
cine dose provides a protection efficacy in the range 60%
to 90% against infection, which was sampled for each
vaccinated individual and implemented as a reduction
factor in disease transmission.
Transmissibility
Quantification of the relative transmissibility of ZIKV
asymptomatic infection compared to symptomatic
infection is currently lacking. We therefore considered
two scenarios with transmission factors of 0.1 (low) and
0.9 (high) to quantify this relative transmissibility [18].
Furthermore, the contribution of ZIKV symptomatic
infection to the overall disease spread has not been esti-
mated. In the absence of such estimates, we also consid-
ered two scenarios with reduction factors of 0.1 and 0.5
for symptomatic transmission to account for decreased
mobility and lower exposure to mosquito bites through
full clothing, mosquito repellents, or possible isolation
during symptomatic infection [18]. The risk of sexual
transmission was sampled for each encounter in the
range of 1% to 5% [18].
Cost-effectiveness analysis
We conducted the cost-effectiveness analysis from a gov-
ernment perspective and included only direct medical costs.
The health impact of microcephaly and GBS to an individ-
ual’s quality of life was captured by disability-adjusted life
years (DALYs), as recommended in the 1996 Global Burden
of Disease study [31]. Based on the estimates for other flavi-
virus vaccines, we considered a range of US$2 to US$50 for
vaccination costs per individual [32], including vaccine
dose, administration, and 3% wastage. For a given price, the
incremental cost-effectiveness ratio (ICER) of 5000 simula-
tion runs was calculated using the formula:
ICER ¼ CostVaccination−CostNo Vaccination
− DALYVaccination−DALYNo Vaccinationð Þ
We calculated the average ICER values and the associ-
ated 95% confidence interval using a non-parametric
bootstrap method of 2000 replicates, and constructed
the cost-effectiveness plane and acceptability probabil-
ities to offer a visual representation of the joint distribu-
tion of costs and benefits. All costs were reported in
2017 US dollars. A discount rate of 3% was applied to
both the costs and DALY calculations to consider prefer-
ence for present value.
Results
We ran 5000 independent Monte Carlo simulations of
ZIKV infection dynamics with a scaled-down population of
10,000 individuals. Each simulation was seeded with a single
ZIKV latent case and run for a time horizon of 1 year (Add-
itional file 1: Figures S3–S6). Disease outcomes and vaccin-
ation throughout each simulation were recorded and used
to calculate ICER values and cost-effectiveness probability.
Vaccine cost-effectiveness
We first considered R0 = 2.2 as the mean of a previously
estimated range, which also lies within the range of esti-
mates reported in previous studies for ZIKV spread in
Latin and South America [27, 28]. With a relatively low
reduction (10% on average) of transmission from ZIKV
symptomatic infection, the ICER values for a range of
vaccine costs per individual were calculated (Fig. 1). In a
fully susceptible population, with a low (10%) relative
transmissibility of asymptomatic infection (Fig. 1a), the
ICER values and their associated ranges remained nega-
tive for 100% of simulation results when vaccination
costs per individual (VCPI) were US$6 or less. These re-
sults suggest that the vaccine is cost-saving regardless of
the thresholds of willingness-to-pay (Fig. 2a).
For VCPI with positive ICER values (Fig. 1a), we con-
sidered a range of willingness-to-pay values. At the con-
servative threshold of US$6610 per DALY averted,
corresponding to the average per capita GDP of Colombia
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from 2013 to 2017, the ZIKV vaccine was highly
cost-effective with a probability of at least 90% at a VCPI
of US$10 or less (Fig. 2a). Increasing the threshold to
US$19,832 (three times the average GDP) [32], our results
suggest that vaccination would still be cost-effective for
VCPI up to US$16. The probability of cost-effectiveness
was sensitive to VCPI and decreased sharply from 90% to
below 10% with a marginal increase in the VCPI.
When the transmissibility of asymptomatic infection
was relatively high (90%), then vaccination was cost-saving
for VCPI up to US$12, as suggested by the negative ICER
values (Fig. 1b). For positive ICER values, vaccination was
highly cost-effective at US$6610 willingness-to-pay per
Table 1 Parameter values and their associated ranges used for
simulations and cost-effectiveness analysis
Parameter description Baseline value (range) Source
Transmission
probability for
infection
Baseline for R0 = 2.2 [27]
Human to mosquito 0.2851 to 0.3947
depending on the
assumed relative
transmissibility of
asymptomatic
infection compared to
symptomatic infection
from 0.9 down to 0.1
Transmissibility was
estimated by
calibrating the model
to the basic
reproduction number
in the range 1.9–2.8
[18]
Mosquito to human Assumed the same as
human to mosquito
Relative
transmissibility of
asymptomatic
infection
0.1–0.9 [18]
Human infection parameters
Intrinsic incubation
period
Mean: 5.7 days
(Lognormal); shape =
1.72; scale = 0.21
[37, 38]
Infectious period Mean: 4.7 days
(Lognormal); shape =
1.54; scale = 0.12
[18, 39]
Risk of infection
through sexual
encounter
1–5% [18]
Fraction of infected
cases experiencing
asymptomatic
infection
40–80% [7, 8]
Risk of Guillain–Barré
Syndrome (GBS)
0.025–0.06% [26]
Mosquito lifespan and infection parameters
Seasonal lifespan
determined by a
hazard function
(Additional file 1)
Mean for high
temperature season:
19.6 days
Mean for low
temperature season:
11.2 days
[18]
Extrinsic incubation
period
Mean: 10 days
(Lognormal); shape =
2.28; scale = 0.21
[40]
Number of
mosquito bites
Determined by
Poisson sampling with
the mean of half-life
for each mosquito
[18]
Risk of microcephaly
First trimester (ends
at 97 days of
pregnancy)
5–14% [12, 20, 21]
Second and third
trimester
3–5%
Life expectancy
Without microcephaly 70 years [24]
With microcephaly 35 years
Table 1 Parameter values and their associated ranges used for
simulations and cost-effectiveness analysis (Continued)
Parameter description Baseline value (range) Source
Probability of
survival past first
year of life for
infants with
microcephaly
0.798 [23]
Pre-existing level of herd immunity
From previous
outbreaks
8% (2.2–11%) [18, 28]
Vaccination coverage
Non-pregnant
women from 15 to
49 years of age
60% Assumed
Pregnant women 80%
Other individuals from
9 to 60 years of age
10%
Vaccine efficacy
Preventing infection 60–90% Assumed; sampled for
each vaccinated
individual
Costs
Direct medical costs
of microcephaly
US$91,925 per lifetime [24, 30]
Direct medical costs
of GBS
US$29,027 per lifetime
Costs of physician
visit for symptomatic
cases
US$65 [29]
Zika test for
symptomatic
pregnant women
US$150 [30]
Vaccine costs per
individual (includes
dose, transportation,
administration,
wastage)
US$2–$50 Assumed [32]
Cost-effectiveness rates
Disability weight for
microcephaly
0.16 [25]
Annual discount rate 3% Assumed
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DALY averted at a VCPI of US$16 or less (Fig. 2b). At
three times the GDP threshold of willingness-to-pay
(US$19,832), vaccination was still cost-effective for VCPI
up to US$29.
We investigated similar scenarios in the presence of
pre-existing immunity as a result of previous outbreaks.
We used estimates of attack rates with the mean of 8%
(95% CI 4–26%) [18, 28] to account for herd immunity
in the population. When the relative transmissibility of
asymptomatic infection was low (10%), the ICER values
and their associated ranges were negative for VCPI up to
US$4 (Fig. 1c). For positive ICER values, vaccination
remained highly cost-effective (with a probability of at
least 90%) at the US$6610 threshold of willingness-to-pay
per DALY averted when the VCPI did not exceed US$7
(Fig. 2c). At the threshold of three times the average GDP,
vaccination was still cost-effective for VCPI up to US$13.
With the same level of herd immunity, but a higher
relative transmissibility of asymptomatic infection (90%),
vaccination was cost-saving (with negative ICER values)
for VCPI up to US$6 (Fig. 1d). When ICER values were
positive, vaccination was highly cost-effective at a VCPI of
US$8 or less, and cost-effective at a VCPI of US$14 or less
at the willingness-to-pay thresholds of US$6610 and
US$19,832, respectively (Fig. 2d).
In order to evaluate the vaccine cost-effectiveness in a
population setting with a higher transmissibility, we con-
sidered the corresponding scenarios with R0 = 2.8. Com-
pared to the case of R0 = 2.2, Figs. 3 and 4 indicate that
vaccination is highly cost-effective for a larger range of
VCPI, in particular when the reduction of transmission
from ZIKV symptomatic infection is relatively low (10%
on average). Table 2 summarizes simulation outcomes
for VCPI in each scenario.
As the contribution of ZIKV symptomatic infection to
disease spread decreases (e.g., reduction of 50%), a lower
VCPI and a higher willingness-to-pay were required for
the vaccine to be cost-effective (Additional file 1). We
observed similar trends when the corresponding scenar-
ios were simulated with an average of 8% pre-existing
level of herd immunity in the population.
Effect of vaccination on microcephaly
We used the cumulative number of fetal microcephaly
cases following ZIKV infection during pregnancy at the end
of each simulation in the absence and presence of vaccin-
ation. Percentage reduction of microcephaly due to vaccin-
ation was calculated using 2000 bootstrap replications. In
all scenarios investigated for vaccine cost-effectiveness, the
median percentage reduction of microcephaly exceeded
64% (Figs. 5 and 6), suggesting that a vaccine with protec-
tion efficacy as low as 60% could significantly reduce the in-
cidence of microcephaly.
Discussion
In this study, we evaluated the cost-effectiveness of a Zika
vaccine candidate from a government perspective under a
number of plausible scenarios. Using an agent-based model
of ZIKV transmission dynamics, we determined the VCPI
for each scenario, below which vaccination was cost-saving
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Fig. 1 Boxplots for ICER values obtained using bootstrap method for a range of VCPI with R0=2.2. Subplots correspond to the scenarios without
pre-existing immunity (a, b), and with an average of 8% pre-existingimmunity (c, d) in the population. The relative transmissibility of asymptomatic
infection was set to 10% (a, c) and 90% (b, d). Solid (grey) line represents the willingness-to-pay threshold corresponding to the averageof per capita
GDP of Colombia between 2013 and 2017
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(when ICER values were negative) and highly cost-effective
(when ICER values were positive, below the threshold of
willingness-to-pay). Our analysis was based on using direct
medical cost estimates associated with the treatment of
symptomatic Zika infection, GBS cases, and long-term
neurological sequelae caused by microcephaly condition.
The results show that, in a population setting with similar
characteristics to Colombia, targeted vaccination of women
of reproductive age would be cost-saving in an outbreak
response if VCPI was sufficiently low (i.e., scenario
dependent), and cost-effective for a wide range of VCPI
values between thresholds of one and three times per capita
GDP. Although the likelihood of cost-effectiveness was
shown to be sensitive to willingness-to-pay and vaccination
a b
c d
Fig. 2 Probabilities of vaccine being cost-effective for a range of VCPI and willingness-to-pay, with R0 =2.2. Subplots correspond to the scenarios
without pre-existing immunity (a, b), and with an average of 8% pre-existingimmunity (c, d) in the population. The relative transmissibility of
asymptomatic infection was set to 10% (a,c) and 90% (b,d). Solid line represents the willingness-to-pay threshold corresponding to the average of
per capita GDP of Colombia between 2013 and 2017. Dashed line represents three times the average of per capita GDP of Colombia. The red
curve represents the 90% probability of vaccine being cost-effective for a given VCPI
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Fig. 3 Boxplots for ICER values obtained using bootstrap method for a range of VCPI with R0 =2.8. Subplots correspond to the scenarios without
pre-existing immunity (a, b), and with an average of 8% pre-existing immunity (c, d) in the population. The relative transmissibility of asymptomatic
infection was set to 10% (a, c) and 90% (b, d). Solid (grey) line represents the willingness-to-pay threshold corresponding to the average of per capita
GDP of Colombia between 2013 and 2017
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costs, the largest range of VCPI for cost-effectiveness corre-
sponded to scenarios in which the population is fully sus-
ceptible or the effect of other interventions to blunt ZIKV
transmission is relatively low. However, non-pharmaceutical
measures (including vector control programs), increased ac-
cess to contraception [33], and pre-existing herd effects as a
result of naturally acquired immunity in previous outbreaks
could decrease the range of VCPI for cost-effectiveness, re-
quiring a significantly higher willingness-to-pay for vaccin-
ation to prove cost-effective. In all scenarios, vaccination
with an individual-level protection efficacy sampled in the
range 60% to 90% resulted in a median reduction of micro-
cephaly that exceeded 64% compared with no vaccination.
To our knowledge, this study presents the first
cost-effectiveness analysis of a Zika vaccine candidate. We
performed cost-effectiveness analysis using an individual-level
stochastic approach and employed a bootstrap sampling
method, which account for parameter uncertainty. A
key strength of our modeling approach is that, unlike
state-transition and static models, it inherently takes
into account the indirect protection effects of naturally
acquired and vaccine-induced immunity in the popula-
tion. However, this study has several limitations arising
from the lack of data and evidence. First and foremost
is the lack of vaccine efficacy data in humans. While
Zika virus challenge in rhesus monkeys has shown a
high level of neutralizing antibodies for complete pro-
tection in a number of vaccine platforms [34], such in-
formation is currently unavailable for humans. The
efficacy data can also provide information on the num-
ber of vaccine doses required, which would affect the
vaccination costs per individual. In the absence of such
information, we considered a single dose of vaccine
with protection efficacy of 60% to 90%. We also
assumed that the risk of microcephaly is independent
of vaccine-induced immunity in a vaccinated pregnant
a b
c d
Fig. 4 Probabilities of vaccine being cost-effective for a range of VCPI and willingness-to-pay, with R0 =2.8. Subplots correspond to the scenarios
without pre-existing immunity (a, b), and with an average of 8% pre-existingimmunity (c, d) in the population. The relative transmissibility of
asymptomatic infection was set to 10% (a,c) and 90% (b, d). Solid line represents the willingness-to-pay threshold corresponding to the average
of percapita GDP of Colombia between 2013 and 2017. Dashed line represents three times the average of per capita GDP of Colombia. The red
curve represents the 90% probability of vaccine being cost-effective for a given VCPI
Table 2 Upper range of vaccination costs per individual (US dollar) for a Zika vaccine candidate to be cost-saving (ICER < 0), highly
cost-effective (WTP of per capita GDP) or cost-effective (WTP of three times per capita GDP)
0% herd immunity 8% herd immunity
RTA 10% 90% 10% 90%
WTP WTP WTP WTP
R0 ICER < 0 $6610 $19,832 ICER < 0 $6610 $19,832 ICER < 0 $6610 $19,832 ICER < 0 $6610 $19,832
2.2 $6 $10 $16 $12 $16 $29 $4 $7 $13 $6 $8 $14
2.8 $29 $38 $53 $35 $45 $66 $16 $22 $35 $20 $27 $45
ICER incremental cost-effectiveness ratio, RTA relative transmissibility of asymptomatic infection, WTP willingness-to-pay
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woman if infection occured. In the absence of
pre-existing immunity, clinical and epidemiological
studies [7, 8] indicate that a significant portion (up to
80%) of ZIKV-infected individuals experience asymp-
tomatic infection without presenting clinical symptoms.
We assumed that vaccine-induced immunity further
reduces the chance of clinical manifestation (if infection
occurred), and therefore considered infection following
vaccination to be asymptomatic. Validation of this as-
sumption requires efficacy data from clinical trials,
which are currently lacking. However, in terms of costs
associated with microcephaly (which dominate), we
a b
c d
Fig. 5 Distribution of percentage reduction of microcephaly obtained using bootstrap method, with R0 =2.2. Subplots correspond to the
scenarios without pre-existing immunity (a, b), and with an average of 8% pre-existingimmunity (c, d) in the population. The relative
transmissibility of asymptomatic infection was set to 10% (a ,c) and 90% (b, d). The median percentage reduction is (a) 0·739 (IQR: 0·715 – 0·759);
(b) 0·723 (IQR: 0·709-0·736); (c) 0·687 (IQR: 0·652 – 0·717); (d) 0·711 (IQR: 0·694 – 0·728)
a b
c d
Fig. 6 Distribution of percentage reduction of microcephaly obtained using bootstrap method, with R0 =2.8. Subplots correspond to the
scenarios without pre-existing immunity (a, b), and with an average of 8% pre-existing immunity (c, d) in the population. The relative
transmissibility of asymptomatic infection was set to 10%(a, c) and 90% (b, d). The median percentage reduction is (a) 0·699 (IQR: 0·687 – 0·712);
(b) 0·695 (IQR: 0·687-0·704); (c) 0·666 (IQR: 0·649 – 0·683); (d) 0·670 (IQR: 0·658 – 0·682).
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expect our results of cost-effectiveness analysis to hold
because we did not alter the risk of microcephaly in the
presence of vaccine-induced immunity in pregnant
women. Without the outcomes of clinical trials, our
model did not consider the possible adverse side effects
of vaccination and their associated costs. Although,
other neurological disorders have been reported in as-
sociation with ZIKV infection (including encephalitis,
meningoencephalitis, myelitis, and optical neuritis)
[35], we considered only microcephaly and GBS out-
comes. In the context of cost-effectiveness analysis
from a government perspective, our analysis excluded
indirect costs such as loss of productivity and earnings
in families inflicted by microcephaly and GBS, yet we
understand that the lifetime indirect costs related to
the care of children with microcephaly could be sub-
stantial [30].
In the model presented here, we considered individual in-
teractions only for the implementation of sexual transmis-
sion. Due to the lack of individual movement data, our
model does not include mobility patterns, which may influ-
ence the level of exposure to mosquito bites. We also note
that the risk of sexual transmission may continue for several
days or weeks following recovery from infection [36]. How-
ever, due to the uncertainty of this period at the individual
level [36], we made a simplifying assumption of considering
the risk of sexual transmission only during the infectious
period. Despite these limitations that merit further investiga-
tion, our results suggest that a Zika vaccine has the potential
to significantly reduce the health and economic burden of
ZIKV infection in at-risk populations. In addition to inform-
ing policymakers with cost-effective scenarios of vaccination
and its potential for outbreak containment, this study pre-
sents a comprehensive modeling approach that can be used
to evaluate cost-effectiveness in other population settings
and provide more accurate estimates as vaccine-specific data
become available. Similar to other flavivirus vaccines such as
dengue [32], understanding the effectiveness and health eco-
nomics of a Zika vaccine is an important research priority,
especially in the context of populations where ZIKV vector
carriers (e.g., Aedes aegypti) are endemic.
Conclusions
Our study suggests that a Zika vaccine with protection
efficacy as low as 60% could significantly reduce the inci-
dence of microcephaly. Vaccinating women of repro-
ductive age was shown to be highly cost-effective for a
large range of vaccination costs per individual with the
threshold of willingness-to-pay corresponding to the
average per capita GDP of Colombia between 2013 and
2017. Efficacy data from clinical trials and number of
vaccine doses will be important requirements in future
studies to refine our estimates and to conduct similar
studies in other at-risk populations.
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